Bio-Techne launches multiplex spatial genomics assay

By Samantha Black, PhD, ScienceBoard editor in chief

July 27, 2021 -- Bio-Techne has expanded its Advanced Cell Diagnostics brand's RNAscope in situ hybridization technology portfolio with the release of the new RNAscope HiPlex V2 assay for formalin-fixed, paraffin-embedded (FFPE) and fixed and frozen samples for up to 12 targets.

The RNAscope HiPlex V2 assay is designed to enable a deeper understanding of gene expression patterns at a single-cell resolution. The assay can generate precision expression data from 12 targets in FFPE samples and up to 48 targets in fresh and fixed frozen samples, according to the company.

The new RNAscope HiPlex V2 assay can profile different cell types within the tumor microenvironment.
The new RNAscope HiPlex V2 assay can profile different cell types within the tumor microenvironment. Twelve target-specific marker probes were used to detect immune cells, tumor cells, chemokines, and cytokines in lung cancer. Image courtesy of Advanced Cell Diagnostics.

The assay also allows for direct visualization of the transcript and eliminates the need for bioinformatics methods for analysis and interpretation of single-cell RNA sequencing data. The multiplexed assay can be performed on commonly available laboratory equipment and is customizable with Bio-Techne's catalog of RNAscope probes or custom probes for any target.

Intended for research use only, the new release positions the company to better support the rapidly growing field of spatial genomics.

Bio-Techne opens new facility in Ireland
Bio-Techne has opened a new facility in Dublin as part of its efforts to support the life sciences industry in Europe.
Catamaran Bio, Bio-Techne expand CAR-NK cell collaboration
Catamaran Bio and Bio-Techne have expanded their collaboration on the development of cell engineering and cell process technologies for Catamaran's manufacturing...
Bio-Techne joins Cell and Gene Therapy Catapult PAT consortium
Bio-Techne is joining the Cell and Gene Therapy Catapult process analytical technology (PAT) consortium, which includes over 20 pharmaceutical companies,...
Bio-Techne posts revenue gains in Q3
Bio-Techne reported strong growth in revenues for its third quarter, thanks largely to sales in its protein analysis business.
908 Devices, Bio-Techne partner on protein characterization workflow
908 Devices and Bio-Techne are collaborating to develop an extended workflow solution for protein characterization.

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter